Cantor Fitzgerald Downgrades Tobira Therapeutics (TBRA) to Hold Following Takeover

Cantor Fitzgerald downgraded Tobira Therapeutics (NASDAQ: TBRA) from Buy to Hold with a price target of $42.00 (from $19.00) after the company agreed to be acquired by Allergan.

For an analyst ratings summary and ratings history on Tobira Therapeutics click here. For more ratings news on Tobira Therapeutics click here.

Shares of Tobira Therapeutics closed at $38.91 yesterday.

You May Also Be Interested In

• Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
• Macquarie Downgrades Mando Corp. (204320:KS) (MDOMF) to Neutral
• Citi Downgrades Liberty SiriusXM (LSXMA) to Neutral, 'fairly balanced at prevailing levels'